HCmed Innovations CoTPE:6934 -2.16%11 Return-on-Tangible-Equity is 10.07% as of Dec. 2025. GuruFocus rates TPE:6934 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 759 Medical Devices & Instruments companies, HCmed Innovations Co ranks worse than 67.85% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. HCmed Innovations Co's annualized net income for the quarter that ended in Dec. 2025 was NT$27.81 Mil. HCmed Innovations Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$276.08 Mil. Therefore, HCmed Innovations Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 10.07%.
The historical rank and industry rank for HCmed Innovations Co's Return-on-Tangible-Equity or its related term are showing as below:
TPE:6934'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -90.33 Med: -52.37 Max: -11.15
Current: -11.15
During the past 5 years, HCmed Innovations Co's highest Return-on-Tangible-Equity was -11.15%. The lowest was -90.33%. And the median was -52.37%.
TPE:6934's Return-on-Tangible-Equity is ranked worse than 67.85% of 759
companies
in the Medical Devices & Instruments industry
Industry Median: 4.07
vs TPE:6934: -11.15
HCmed Innovations Co (TPE:6934) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
HCmed Innovations Co Return-on-Tangible-Equity Related Terms
HCmed Innovations Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for HCmed Innovations Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCmed Innovations Co Return-on-Tangible-Equity Chart
TPE:6934 vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, HCmed Innovations Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCmed Innovations Co Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HCmed Innovations Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where HCmed Innovations Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.07% mean?
HCmed Innovations Co (TPE:6934) has a Return-on-Tangible-Equity of 10.07% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on HCmed Innovations Co and its competitors. According to the industry distribution chart, HCmed Innovations Co ranks #515 out of 759 companies in the Medical Devices & Instruments industry, placing it in the top 67.9%.
Is HCmed Innovations Co's Return-on-Tangible-Equity too high?
HCmed Innovations Co's current Return-on-Tangible-Equity is 10.07%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.07. HCmed Innovations Co's value of 10.07% is 147.4% above this industry median. Based on the distribution chart, HCmed Innovations Co ranks #515 out of 759 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, HCmed Innovations Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does HCmed Innovations Co's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HCmed Innovations Co ranks #515 out of 759 companies for Return-on-Tangible-Equity. This places HCmed Innovations Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.07. HCmed Innovations Co's value of 10.07% is 147.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.07, based on 759 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HCmed Innovations Co's current Return-on-Tangible-Equity of 10.07% is 147.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on HCmed Innovations Co and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HCmed Innovations Co's current Return-on-Tangible-Equity is 10.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCmed Innovations Co stock overvalued right now?
HCmed Innovations Co (TPE:6934) has a current Return-on-Tangible-Equity of 10.07%. The current Return-on-Tangible-Equity is 10.07% and 147.4% above the Medical Devices & Instruments industry median of 4.07. HCmed Innovations Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For HCmed Innovations Co (TPE:6934), the current Return-on-Tangible-Equity is 10.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HCmed Innovations Co Ltd is engaged in designing, developing, manufacturing and selling drug delivery system. It is focused on inhalation therapy to create integrated drug nebulizer combination products featuring nebulization therapeutic drugs that include small molecule synthetics and large molecule biologics, as either solutions, suspensions, and even difficult-to-deliver high viscosity drugs. Its product includes Pulmogine. Geographically, the company operates in America, Europe, Asian and African regions.
11GF Score
Get the complete analysis for TPE:6934
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6934 has been successfully added to your 
